{
    "nctId": "NCT02157051",
    "briefTitle": "Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer",
    "officialTitle": "A Phase I Trial of the Safety and Immunogenicity of a Multiple Antigen Vaccine (STEMVAC) in HER2 Negative Advanced Stage Breast Cancer Patients",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "HER2 Negative Breast Carcinoma, Recurrent Breast Carcinoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 42,
    "primaryOutcomeMeasure": "Incidence of toxicity per Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events version 4.0",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with stage III-IV HER2 negative breast cancer treated with primary or salvage therapy and now have:\n\n  * No evidence of disease (NED), or\n  * Stable bone only disease\n* Patients who have completed standard of care and recovered with mild to no residual toxicity from recent therapy\n* Patients must be at least 28 days post cytotoxic chemotherapy, and/or monoclonal antibody therapy (excluding bone-directed therapy), prior to enrollment\n* Patients must be at least 28 days post systemic steroids prior to enrollment\n* Patients on bisphosphonates, denosumab, and/or endocrine therapy are eligible\n* Patients must have Eastern Cooperative Oncology Group (ECOG) performance status score of =\\< 1\n* Patients must have recovered from major infections and/or surgical procedures, and in the opinion of the investigator, not have any significant active concurrent medical illnesses precluding protocol treatment\n* Estimated life expectancy of more than 6 months\n* White blood cells (WBC) \\>= 3000/mm\\^3 (within 30 days of first vaccination)\n* Lymphocyte count \\>= 800/mm\\^3 (within 30 days of first vaccination)\n* Platelet count \\>= 75,000/mm\\^3 (within 30 days of first vaccination)\n* Hemoglobin (Hgb) \\>= 10 g/dl (within 30 days of first vaccination)\n* Serum creatinine \\<= 1.2 mg/dl or creatinine clearance \\> 60 ml/min (within 30 days of first vaccination)\n* Total bilirubin \\<= 1.5 mg/dl (within 30 days of first vaccination)\n* Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) \\<= 2 times upper limit of normal (ULN) (within 30 days of first vaccination)\n* Blood glucose \\< 1.5 ULN (within 30 days of first vaccination)\n* All patients who are having sex that can lead to pregnancy must agree to contraception for the duration of study\n\nExclusion Criteria:\n\n* Patients with any of the following cardiac conditions:\n\n  * Symptomatic restrictive cardiomyopathy\n  * Unstable angina within 4 months prior to enrollment\n  * New York Heart Association functional class III-IV heart failure on active treatment\n  * Symptomatic pericardial effusion\n* Patients at risk for gastrointestinal bleeding (example: peptic ulcer disease, prolonged daily non-steroidal anti-inflammatory use)\n* Patients with any seizure disorder\n* Patients with any contraindication to receiving rhuGM-CSF based products\n* Patients with any clinically significant autoimmune disease uncontrolled with treatment\n* Patients who are simultaneously enrolled in any other treatment study\n* Patients who are pregnant or breastfeeding",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}